On Tuesday, Shares of Rite Aid Corporation (NYSE:RAD), gained 2.30% to $8.89.
On June 18, Rite Aid Corporation, stated operating results for its fiscal first quarter ended May 30, 2015. The company stated revenues of $6.6 billion, net income of $18.8 million or $0.02 per diluted share, and Adjusted EBITDA of $299.3 million, or 4.5 percent of revenues.
First Quarter Summary
Revenues for the quarter were $6.6 billion as compared to revenues of $6.5 billion in the preceding year’s first quarter. Revenues raised 2.8 percent primarily as a result of an enhance in same store sales.
Same store sales for the quarter raised 2.9 percent over the preceding year, compriseing of a 0.6 percent enhance in front-end sales and a 3.9 percent enhance in pharmacy sales. Pharmacy sales comprised of an approximate 165 basis point negative impact from new generic introductions. The number of prescriptions filled in same stores raised 1.6 percent over the preceding year period. Prescription sales accounted for 69.1 percent of total drugstore sales, and third party prescription revenue was 97.7 percent of pharmacy sales.
Net income was $18.8 million or $0.02 per diluted share contrast to last year’s first quarter net income of $41.4 million or $0.04 per diluted share. The decline in net income resulted primarily from interest and other incremental pre-tax costs of $36.0 million, or $0.02 per share on an after-tax basis, incurred in connection with the company’s pending acquisition of EnvisionRx. These incremental costs were partially offset by an enhance in Adjusted EBITDA.
Adjusted EBITDA (which is reconciled to net income on the attached table) was $299.3 million or 4.5 percent of revenues for the first quarter contrast to $282.6 million or 4.4 percent of revenues for the like period last year. Adjusted EBITDA improved due to an enhance in front-end and pharmacy gross profit, partially offset by an enhance in selling, general and administrative expenses related to our higher level of sales, clinic expansion and the roll-out of the Plenti program.
In the first quarter, the company relocated 2 stores, remodeled 108 stores and expanded 1 store, bringing the total number of wellness stores chainwide to 1,741. The company also closed 4 stores, resulting in a total store count of 4,566 at the end of the first quarter.
Rite Aid Corporation, through its auxiliaries, operates a chain of retail drugstores in the United States. The company sells prescription drugs and a range of other merchandise, counting over-the-counter medications, health and beauty aids, personal care items, cosmetics, household items, food and beverages, greeting cards, seasonal merchandise, and other every day and convenience products.
Shares of Vical Incorporated (NASDAQ:VICL), declined -43.63% to $0.80, during its last trading session, hitting its lowest level.
Vical Incorporated declared top-line results from an ongoing randomized, double-blind, placebo controlled Phase 1/2 clinical study of its therapeutic genital herpes vaccine, designed to reduce viral shedding and genital herpes lesions in herpes simplex virus type 2 (HSV-2) infected patients. The trial enrolled patients across seven U.S. sites and is evaluating two constructs: a monovalent (gD) vaccine and a bivalent (gD + UL46) vaccine, each formulated with Vical’s proprietary Vaxfectin(R) adjuvant. The top-line analysis contrast pre-vaccination measurements for each arm with those taken during the swabbing period in months 2 and 3 following the last vaccine dose. Neither the monovalent nor bivalent vaccine met the primary endpoint. On prospectively defined secondary endpoints, the bivalent vaccine achieved statistically noteworthy reductions in the rate of genital lesions (-51%, p = 0.0037) and viral load from positive swabs (-0.39 log10, p = 0.0008) as compared to baseline.
Both the monovalent and bivalent vaccines were generally well tolerated. Safety data have been reviewed throughout the trial by an independent safety monitoring board, and no grade 4 adverse events or serious adverse events related to vaccination have been observed.
Vical Incorporated engages in the research and development of biopharmaceutical products based on its DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases.
Finally, Annaly Capital Administration, Inc. (NYSE:NLY), ended its last trade with 0.30% gain, and closed at $9.91, as Financial stocks were finishing moderately higher Tuesday with the NYSE Financial Sector Index climbing about 0.3% and the S&P Financial 100 Index also adding around 0.3%.
Annaly Capital Administration, Inc. owns a portfolio of real estate related investments in the United States. The company invests in various types of agency mortgage-backed securities and related derivatives to hedge these investments; acquires, finances, and manages commercial mortgage loans and other commercial real estate debt, commercial mortgage-backed securities, and other commercial real estate-related assets; and operates as a broker-dealer.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
